SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Amarin Corp. plc and Its Board of Directors and of a Lead Plaintiff Deadline of January 3, 2014

NEW YORK, Dec. 24, 2013

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/amarin-corp-amrn/.

The complaint alleges that Defendants made false and/or misleading statements regarding the likelihood that its drug Vascepa would be approved by the Food and Drug Administration for the ANCHOR indication. It is further alleged that Amarin failed to disclose that the FDA had informed the Company there was a lack of prospective, controlled clinical trial data that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.

On October 11, 2013, Amarin shares fell more than 20% to close at $5.09 after the FDA released its briefing documents for the October 16, 2013 advisory committee review of Amarin's application to expand the use of its drug Vascepa. The FDA briefing documents raised questions about the mineral oil placebo potentially negatively impacting the control group data and consequentially overstating Vascepa's effectiveness. Then on October 30, 2013, Amarin disclosed that the FDA had rescinded the ANCHOR study special protocol assessment agreement. Shares of Amarin closed at $1.64 per share on November 1, 2013.

If you suffered a loss in Amarin you have until January 3, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/amarin-corp-amrn/.  

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.